Article

Ranibizumab shows promise for DME

The primary endpoint has been met in one of two phase 3 studies evaluating monthly ranibizumab injection (Lucentis, Genentech) in patients with diabetic macular edema (DME), according to the company.

South San Francisco-The primary endpoint has been met in one of two phase III studies evaluating monthly ranibizumab injection (Lucentis, Genentech) in patients with diabetic macular edema (DME), according to the company.

In the RISE study, a significantly higher percentage of patients receiving monthly ranibizumab saw an improvement in best-corrected visual acuity of at least 15 letters on the eye chart at 24 months, compared with those in a control group, who received a placebo injection. A preliminary analysis of the data did not reveal any unexpected safety signals; further analyses are ongoing.

“DME is a leading cause of blindness among working-aged adults in most developed countries, and currently there are no FDA-approved medicines to treat patients who suffer from this debilitating condition,” said Hal Barron, MD, chief medical officer and head of global product development for Genentech. “We are encouraged by these data and await the results of RIDE, our other pivotal study in DME.”

RISE and RIDE are two identical, parallel confirmatory studies designed to support application to the FDA for a potential new indication for ranibizumab for DME.

In the United States, ranibizumab is approved for the treatment of neovascular age-related macular degeneration and for the treatment of macular edema following retinal vein occlusion. In Europe, where the drug is marketed by Novartis, it recently was approved to treat visual impairment due to DME.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.